Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Stock Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1276 Analyst Ratings

Moderate Buy

3 Buy

1 Hold

1 Sell

Based on 5 analysts giving stock ratings to

Jiangsu

Hengrui Pharmaceuticals Co., Ltd. Class H

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1276 Stock 12 Month Forecast

Average Price Target

HK$87.98

▲(14.63% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H in the last 3 months. The average price target is HK$87.98 with a high forecast of HK$108.00 and a low forecast of HK$69.50. The average price target represents a 14.63% change from the last price of HK$76.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"HK$52","109":"HK$109","66.25":"HK$66.3","80.5":"HK$80.5","94.75":"HK$94.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$108.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87.98,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$87.98</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$69.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,66.25,80.5,94.75,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.85,75.55384615384615,78.25769230769231,80.96153846153845,83.66538461538461,86.36923076923077,89.07307692307693,91.77692307692308,94.48076923076923,97.18461538461538,99.88846153846154,102.59230769230768,105.29615384615386,{"y":108,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.85,74.01384615384615,75.1776923076923,76.34153846153846,77.50538461538461,78.66923076923077,79.83307692307692,80.99692307692308,82.16076923076923,83.32461538461538,84.48846153846154,85.6523076923077,86.81615384615385,{"y":87.98,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.85,72.59230769230768,72.33461538461538,72.07692307692307,71.81923076923077,71.56153846153846,71.30384615384615,71.04615384615384,70.78846153846153,70.53076923076922,70.27307692307693,70.01538461538462,69.75769230769231,{"y":69.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.7,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.7,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":57.7,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.8,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":53.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$108.00

Average Price TargetHK$87.98

Lowest Price TargetHK$69.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anita Wei

UBS

HK$97.8→HK$96.9

Buy

26.25%

Upside

Reiterated

12/05/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$111→HK$108

Buy

40.72%

Upside

Reiterated

11/10/25

Citic Securities Sticks to Its Buy Rating for Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276)

Alexis Yan

Morgan Stanley

HK$86

Buy

12.05%

Upside

Reiterated

10/28/25

Unknown Analyst

Daiwa

Not Ranked

Daiwa

HK$86→HK$79.5

Sell

3.58%

Upside

Reiterated

10/28/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$69.5

Hold

-9.45%

Downside

Reiterated

10/28/25

Jialin Zhang

Nomura

HK$94.54

Buy

23.18%

Upside

Reiterated

09/25/25

Nomura Reaffirms Their Buy Rating on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276)

Yang Huang

J.P. Morgan

HK$78

Hold

1.63%

Upside

Initiated

09/23/25

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Initiated with a Hold at J.P. MorganJPMorgan analyst Yang Huang initiates coverage on Jiangsu Hengrui Pharmaceuticals (1276:HK) with a Neutral rating and a price target of HK$78.00.

Tony Ren

Macquarie

HK$92→HK$98

Buy

27.69%

Upside

Reiterated

09/08/25

Macquarie Remains a Buy on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276)Macquarie analyst Tony Ren raised the price target on Jiangsu Hengrui Pharmaceuticals (1276:HK) to HK$98.00 (from HK$92.00) while maintaining a Outperform rating.

Jamie Wang

Citi

HK$134

Buy

74.59%

Upside

Initiated

07/10/25

Citi Initiates a Buy Rating on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anita Wei

UBS

HK$97.8→HK$96.9

Buy

26.25%

Upside

Reiterated

12/05/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$111→HK$108

Buy

40.72%

Upside

Reiterated

11/10/25

Citic Securities Sticks to Its Buy Rating for Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276)

Alexis Yan

Morgan Stanley

HK$86

Buy

12.05%

Upside

Reiterated

10/28/25

Unknown Analyst

Daiwa

Not Ranked

Daiwa

HK$86→HK$79.5

Sell

3.58%

Upside

Reiterated

10/28/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$69.5

Hold

-9.45%

Downside

Reiterated

10/28/25

Jialin Zhang

Nomura

HK$94.54

Buy

23.18%

Upside

Reiterated

09/25/25

Nomura Reaffirms Their Buy Rating on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276)

Yang Huang

J.P. Morgan

HK$78

Hold

1.63%

Upside

Initiated

09/23/25

Tony Ren

Macquarie

HK$92→HK$98

Buy

27.69%

Upside

Reiterated

09/08/25

Jamie Wang

Citi

HK$134

Buy

74.59%

Upside

Initiated

07/10/25

Citi Initiates a Buy Rating on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

1 Month

xxx

Success Rate

2/2 ratings generated profit

Average Return

+8.50%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +8.50% per trade.

3 Months

xxx

Success Rate

2/3 ratings generated profit

Average Return

+17.77%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +17.77% per trade.

1 Year

Alexis YanMorgan Stanley

Success Rate

2/3 ratings generated profit

Average Return

+12.20%

reiterated a buy rating 3 months ago

Copying Alexis Yan's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +12.20% per trade.

2 Years

xxx

Success Rate

2/3 ratings generated profit

Average Return

+12.50%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +12.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1276 Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1276 has received 3 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. 1276 average Analyst price target in the past 3 months is 87.98.

Each month's total comprises the sum of three months' worth of ratings.

1276 Financial Forecast

1276 Earnings Forecast

Next quarter’s earnings estimate for 1276 is HK$0.49 with a range of HK$0.39 to HK$0.64. The previous quarter’s EPS was HK$0.22. 1276 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 1276 has Performed in-line its overall industry.

1276 Sales Forecast

Next quarter’s sales forecast for 1276 is HK$11.11B with a range of HK$9.92B to HK$12.29B. The previous quarter’s sales results were HK$8.12B. 1276 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 1276 has Performed in-line its overall industry.

1276 Stock Forecast FAQ

What is HK:1276’s average 12-month price target, according to analysts?

Based on analyst ratings, Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s 12-month average price target is 87.98.

What is HK:1276’s upside potential, based on the analysts’ average price target?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has 14.63% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H a Buy, Sell or Hold?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 1 hold ratings and 1 sell ratings.

What is Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s share price target?

The average share price target for Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H is 87.98. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$108.00 ,and the lowest forecast is HK$69.50. The average share price target represents 14.63% Increase from the current price of HK$76.75.

What do analysts say about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H?

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H?

To buy shares of HK:1276, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H (1276) Stock Forecast & Price Target

1276 Analyst Ratings

1276 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

1276 Analyst Recommendation Trends

1276 Financial Forecast

1276 Earnings Forecast

1276 Sales Forecast

1276 Stock Forecast FAQ

Detailed List of Analyst Forecasts